Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA.
| Revenue (Most Recent Fiscal Year) | $152.31M |
| Net Income (Most Recent Fiscal Year) | $-80.94M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 1.99 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.83 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -68.35% |
| Net Margin (Trailing 12 Months) | -68.35% |
| Return on Equity (Trailing 12 Months) | -28.68% |
| Return on Assets (Trailing 12 Months) | -21.05% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.86 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.86 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $8.90 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.49 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.00 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.46 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 28.41M |
| Free Float | 23.70M |
| Market Capitalization | $194.06M |
| Average Volume (Last 20 Days) | 0.88M |
| Beta (Past 60 Months) | 2.10 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 94.54% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |